Telix Pharmaceuticals Posts $247M Q2 Revenue, Up 21% YoY Fueled by PSMA Imaging Growth

Precision Medicine Segment Drives Robust Growth Through PSMA Imaging Expansion

Telix’s Precision Medicine division, primarily comprising sales of PSMA-targeting diagnostic agents Illuccix and Gozellix, generated US$202 million in Q2 2026 revenue, reflecting a strong 30% year-over-year increase and 9% sequential growth from Q1 2026’s US$186 million. This segment now stands as Telix’s largest revenue contributor, demonstrating sustained global demand for non-invasive prostate-specific membrane antigen positron emission tomography imaging. U.S. dose volumes rose 7% during the quarter, propelled by expanding adoption of Gozellix alongside continued strength across Telix’s broader PSMA imaging portfolio.

Leveraging clinical evidence from the completed PRIMARY and PRIMARY 2 studies, Telix is expanding the market opportunity for its PSMA imaging agents in initial prostate cancer diagnosis. The BiPASS study, assessing Illuccix and Gozellix for pre-biopsy diagnostic imaging in newly suspected prostate cancer patients, reached rapid enrollment of 338 patients by Q2 2026. Enrollment is nearing completion, positioning the trial to support regulatory submissions in key markets including the U.S., Europe, and Australia. This pre-biopsy indication expansion offers a significant commercial opportunity by extending PSMA imaging use earlier in the prostate cancer diagnostic pathway, potentially reaching a much larger patient population than current advanced disease staging applications.

Japan Regulatory Advances and Conditional Approval Pathway for Illuccix

During the quarter, Telix completed patient enrollment in Japan for the Phase 3 registrational study of TLX591-Px, commercially known as Illuccix. The company is preparing a New Drug Application (NDA) for submission to Japanese regulators, supported by clinical data from this local Phase 3 study. Concurrently, Telix submitted an application for Conditional Approval to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), which, if granted, could expedite NDA review while final clinical data is finalized.

This dual-track regulatory approach in Japan represents a key geographic expansion for Telix’s established PSMA imaging franchise. Japan’s significant prostate cancer prevalence and PET imaging infrastructure make it a strategic market. The Conditional Approval pathway could accelerate patient access to Illuccix while enabling a streamlined NDA review, reflecting Telix’s strategy to balance rapid patient access with ongoing data generation to reduce time-to-market in this important Asian market.

FDA Clearance to Progress TLX591-Tx ProstACT Phase 3 Trial to Part 2

In Q2 2026, Telix reached a major regulatory milestone when the FDA confirmed that safety data from Part 1 of the ProstACT Global Phase 3 trial supports progression to Part 2 in the U.S. The company also aligned with the FDA on the Part 2 clinical protocol, statistical analysis plan, and ongoing safety monitoring for TLX591-Tx (lutetium Lu-177 rosopatamab tetraxetan), its lead therapeutic candidate for metastatic castration-resistant prostate cancer (mCRPC). Part 2 initiation in the U.S. remains subject to FDA review of an Investigational New Drug (IND) amendment.

Part 2 enrollment continues robustly in open regions including Australia, New Zealand, Canada, Türkiye, the U.K., Singapore, and South Korea, with regulatory approval granted to start enrollment in China. This broad geographic recruitment enhances the international clinical evidence base for TLX591-Tx and supports regulatory filings across multiple key markets. The FDA’s confirmation validates the compound’s tolerability and de-risks a critical development milestone for this potential prostate cancer therapy.

Next-Gen PSMA Radioligand TLX597-Tx Advances to Phase 2 in Metastatic Hormone-Sensitive Prostate Cancer

Telix advanced its PSMA-targeted radioligand therapy pipeline by moving TLX597-Tx (Lu-177-DOTA-HYNIC-panPSMA) into a Phase 2 trial. The OPTIMAL-PSMA study for mCRPC completed enrollment of 120 patients. Building on these results, the OPTIMAL-e Phase 2 study has dosed initial patients, evaluating TLX597-Tx in metastatic hormone-sensitive prostate cancer (mHSPC), an earlier disease stage than mCRPC.

Designed as a next-generation small molecule PSMA-targeting radioligand therapy, TLX597-Tx aims to improve efficacy and quality of life in earlier metastatic prostate cancer. Expansion into mHSPC could significantly broaden the eligible patient population, as earlier-stage metastatic disease affects more patients than CRPC. This program is part of Telix’s multi-candidate therapeutic pipeline strategy targeting leadership across advanced prostate cancer stages.

Renal Cell Carcinoma Program Initiates Dosing in Pivotal TLX250-Tx LUTEON Trial

Telix dosed the first patient in the LUTEON trial during Q2 2026, a pivotal Phase 3 study assessing TLX250-Tx (lutetium Lu-177 girentuximab tetraxetan) as monotherapy in advanced clear cell renal cell carcinoma (ccRCC). LUTEON will compare TLX250-Tx efficacy against investigator’s choice monotherapy consistent with standard care. Part 1 aims to enroll up to 40 patients.

This marks Telix’s expansion beyond prostate cancer into solid tumor oncology, diversifying its therapeutic pipeline into renal malignancies. Advanced ccRCC has significant unmet needs with limited treatment options, especially for patients unsuitable for existing therapies. Successful development of TLX250-Tx could open a new therapeutic market segment and reduce pipeline concentration risk. The girentuximab approach targets carbonic anhydrase IX expression in ccRCC, distinct from PSMA-targeting prostate cancer therapies.

Glioblastoma Pipeline Progresses with IPAX BrIGHT Enrollment and IPAX-2 Completion

In Q2 2026, Telix enrolled the first patient cohort in Part 1 of IPAX BrIGHT, an international pivotal trial of TLX101-Tx (iodine I-131 iodofalan) for recurrent glioblastoma. Part 1 evaluates safety and dose optimization. The trial is enrolling in Australia, Austria, the Netherlands, and Belgium, with approvals sought elsewhere. Part 1 plans to enroll up to 40 patients.

Simultaneously, Telix completed enrollment in IPAX-2, a Phase 1 study of TLX101-Tx in newly diagnosed glioblastoma patients, with no dose-limiting toxicities observed. This glioblastoma program expands Telix’s CNS malignancy footprint, addressing a cancer with poor prognosis and limited recent treatment advances. These trials position TLX101-Tx for both recurrent and newly diagnosed glioblastoma, potentially broadening clinical utility if efficacy is demonstrated. Additionally, Telix submitted an IND to the FDA for Pixclara, a Phase 3 study of TLX101-Px (18F-FET floretyrosine PET imaging agent) to expand indications into brain metastases diagnosis, extending its CNS oncology diagnostic portfolio.

Pixclara Brain Metastases IND Filed and NDA Resubmission Receives September 2026 PDUFA Date

Telix submitted an Investigational New Drug (IND) application to the FDA for Pixclara’s Phase 3 registrational study targeting brain metastases diagnosis. The FDA accepted Telix’s resubmitted New Drug Application (NDA) for Pixclara and assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026, clarifying the NDA review timeline for this brain imaging diagnostic agent.

The NDA acceptance and September PDUFA date mark significant regulatory progress for Pixclara’s current indication and suggest potential near-term resolution of the review. The concurrent Phase 3 indication expansion into brain metastases reflects Telix’s strategy to broaden diagnostic imaging applications post-approval. Brain metastases are a common advanced cancer complication across multiple primaries, representing a substantial patient population if approved.

Strategic Partnership with Regeneron Boosts Next-Gen Radiopharmaceuticals Targeting Lung Cancer

Telix entered a strategic collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially focusing on lung cancer. Regeneron provided a US$40 million non-refundable payment to Telix in Q2 2026. This partnership validates Telix’s radiopharmaceutical platform and supplies capital to accelerate development.

Focusing on lung cancer extends Telix’s PSMA expertise to other tumor-associated antigens. Lung cancer is the leading cause of cancer mortality globally, encompassing large patient populations across non-small cell and small cell lung cancers. The collaboration leverages Regeneron’s commercial and oncology expertise alongside Telix’s radiopharmaceutical capabilities. The non-refundable payment offers committed funding for R&D without near-term commercialization pressure, reducing execution risk for early-stage programs.

FY 2026 Revenue Guidance on Track for Upper Range; Increased R&D Investment to Accelerate Pipeline

Telix projects full-year 2026 revenue and other income to exceed US$1 billion, consistent with the upper end of its FY 2026 guidance range of US$950 million to US$970 million plus the US$40 million Regeneron payment. This outlook reflects ongoing Precision Medicine momentum and contributions from Telix Manufacturing Solutions (TMS), which generated US$45 million in Q2 2026 revenue (down 6% year-over-year but up 2% sequentially). The company raised FY 2026 R&D expenditure guidance to US$230 million to US$270 million, enabled by strong commercial results and the Regeneron payment.

The increased R&D spending reflects Telix’s strategic focus on accelerating high-value clinical and development programs across its therapeutic pipeline. Capital allocation prioritizes late-stage trials including ProstACT Global, OPTIMAL-PSMA, OPTIMAL-e, LUTEON, and IPAX BrIGHT. Strong cash flow from Precision Medicine operations provides financial flexibility to fund expanded R&D without significant shareholder dilution, positioning Telix to advance multiple late-stage programs toward regulatory milestones. Managing Director and CEO Dr. Christian Behrenbruch emphasized the company’s commitment to investing in R&D to drive future growth and shareholder value.

Telix Manufacturing Solutions Segment Shows Stabilization in Third-Party Revenue

Telix’s Telix Manufacturing Solutions (TMS) segment, which generates third-party revenue mainly through RLS Radiopharmacies (RLS) and excludes Illuccix and Gozellix sales and inter-segment revenue, reported US$45 million in Q2 2026 revenue. This represents a 6% decline year-over-year from US$48 million in Q2 2025 but a 2% sequential increase from US$44 million in Q1 2026. The sequential growth indicates stabilization in TMS third-party revenue following earlier declines.

The TMS business provides a diversified revenue stream independent of Telix’s proprietary products, offering contracted manufacturing services to other radiopharmaceutical companies and enhancing supply chain resilience. Although TMS revenue growth trails the Precision Medicine segment, it remains a significant revenue contributor with potential for margin expansion and service diversification as the radiopharmaceutical market evolves. Management highlighted that TMS infrastructure supports Telix’s competitive positioning by combining supply chain reliability with clinical differentiation in the precision medicine sector.